

VENTOLIN[®] INJECTION

SCHEDULING STATUS:

S4

PROPRIETARY NAME AND DOSAGE FORM:

VENTOLIN[®] INJECTION

COMPOSITION:

Ampoules of 1 ml each of which contains salbutamol sulphate B.P. equivalent to 0,5 mg (500 µg) salbutamol in a sterile isotonic solution.

PHARMACOLOGICAL CLASSIFICATION:

A.10.2.2 Bronchodilators - other

PHARMACOLOGICAL ACTION:

Salbutamol B.P. is a beta-adrenergic stimulant which has a selective action on the β_2 -adrenoceptors throughout the body.

INDICATIONS:

1. Use in Asthma:

VENTOLIN INJECTION is indicated for the relief of severe bronchospasm associated with asthma or bronchitis and for the treatment of status asthmaticus.

2. Use in Obstetrics:

VENTOLIN INJECTION is indicated in the management of premature labour where it is desirable to suppress uterine contractions.

CONTRA-INDICATIONS:

There are no known contra-indications, but VENTOLIN INJECTION should be administered with caution in patients with hyperthyroidism.

DOSAGE AND DIRECTIONS FOR USE:

1. Use in asthma:

VENTOLIN INJECTION may be administered subcutaneously, intramuscularly or intravenously.

Intramuscular route:

Adults – 500 µg (8 µg/kg body mass) and repeated every four hours as required.

Subcutaneous route:

Adults – 500 µg (8 µg/kg body mass) and repeated every four hours as required.

Intravenous route:

Adults – 250 µg (4 µg/kg body mass) injected slowly. If required for ease of administration VENTOLIN INJECTION may be diluted with Water for Injections B.P., Sodium Chloride Injection B.P., Sodium Chloride and Dextrose Injection B.P., or Dextrose Injection B.P. These are the only recommended diluents and it is inadvisable to administer VENTOLIN INJECTION in a syringe containing any other medication.

NOTE: If VENTOLIN INJECTION must be given to an asthmatic patient in labour it will inhibit uterine contractions. This effect can be counteracted by administration of natural or synthetic oxytocic drugs.

2. Use in obstetrics:

Single intramuscular or intravenous injections may be given to control contractions or to counteract overdose with oxytocic drugs. The usual recommended dose is 100 to 250 µg of salbutamol. The dose may be repeated according to the response of the patient.

SIDE EFFECTS AND SPECIAL PRECAUTIONS:

Unnecessary administration of drugs during the first trimester of pregnancy is undesirable. VENTOLIN INJECTION may dilate some peripheral arterioles leading to a small reduction in arterial pressure and a compensatory increase in cardiac output may then occur. Increases in heart rate are more likely to occur in patients with normal heart rates and these increases are dose dependent. In patients with pre-existing sinus tachycardia, especially those in status asthmaticus, the heart rate tends to fall after VENTOLIN INJECTION as the condition of the patient improves. Slight pain or stinging after injection may occur. VENTOLIN should be administered with caution to patients with co-existing heart disease. Fine tremor of skeletal muscle may occur in some patients, usually the hands being most obviously affected. This effect is dose related and is caused by a direct action on skeletal muscle and is common to all beta-adrenergic stimulants.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:

The specific antidote for overdosage with VENTOLIN INJECTION is a selective beta-blocking agent given by intravenous injection. In general, beta-blocking drugs should be used with caution in patients with a history of bronchospasm or patients who are pregnant.

IDENTIFICATION:

The solution is colourless to very pale straw coloured and odourless. Its specific gravity and viscosity are similar to water.

PRESENTATION:

1 ml ampoules in boxes of 5.

STORAGE INSTRUCTIONS:

Store at or below 30 °C and protect from light.
Keep out of reach of children.

REGISTRATION NUMBER:

H/10.2.2/118

NAME AND BUSINESS ADDRESS OF APPLICANT:

GlaxoSmithKline South Africa (Pty) Ltd
39 Hawkins Avenue
Epping Industria 1, 7460

DATE OF PUBLICATION OF THE PACKAGE INSERT:

11 June 1981

GDS-10

Botswana: Reg No B9303915 **S2**

Namibia: Reg No 90/10.2.2/00588 **NS2**

SKEDULERINGSSTATUS:

S4

EIENDOMSNAAM EN DOSEERVORM:

VENTOLIN® INJECTION (Inspuiting)

SAMESTELLING:

Ampulle met 1 ml. Elk van hierdie ampulle bevat salbutamolsulfaat B.P. gelykstaande aan 0,5 mg (500 µg) salbutamol in 'n steriele isotoniese oplossing.

FARMAKOLOGIESE KLASSIFIKASIE:

A 10.2.2 Brongodilators - ander

FARMAKOLOGIESE WERKING:

Salbutamol B.P. is 'n beta-adrenergiese stimulant wat 'n selektiewe effek op die β_2 -adrenoseptore dwarsdeur die liggaam uitoefen.

INDIKASIES:**1. Gebruik in gevalle van Asma:**

VENTOLIN INJECTION word aangedui vir die verligting van ernstige brongospasma wat met asma en brongitis geassosieer is, en vir die behandeling van status asthmaticus.

2. Gebruik in Verloskunde:

VENTOLIN INJECTION word aangedui vir die behandeling van voortydige baring waar dit wenslik is om uteriensametrekings te onderdruk.

KONTRA-INDIKASIES:

Daar is geen bekende kontra-indikasies nie, maar VENTOLIN INJECTION moet met versigtigheid toegedien word aan persone wat aan hipertireose ly.

DOSIS EN GEBRUIKSAANWYSINGS:**1. Gebruik in gevalle van Asma:**

VENTOLIN INJECTION kan subkutaan, intramuskulêr of intraveneus toegedien word.

Intramuskulêre roete:

Volwassenes – 500 µg (8 µg/kg liggaamsmassa). Dit kan, indien nodig, al om die vier uur herhaal word.

Subkutane roete:

Volwassenes – 500 µg (8 µg/kg liggaamsmassa). Dit kan, indien nodig, al om die vier uur herhaal word.

Intraveneuse roete:

Volwassenes – 250 µg (4 µg/kg liggaamsmassa). Die inspuiting moet stadig toegedien word. Om toediening te vergemaklik kan VENTOLIN INJECTION met Water vir Inspuitings B.P., Natriumchloried-Inspuiting B.P., Natriumchloried en Dekstrose-Inspuiting B.P., of Dekstrose-Inspuiting B.P., verdun word. Hierdie is die enigste verdunningsmiddel wat aanbeveel word, en dit is nie raadsaam om VENTOLIN INJECTION toe te dien met 'n spuit wat enige ander medikament bevat nie.

LET WEL: As VENTOLIN INJECTION gegee moet word aan 'n asmatiese pasiënt in kraam sal dit die sametrekings van die uterus strem. Hierdie effek kan egter teëgewerk word deur die toediening van natuurlike of sintetiese oksitosiese medikamente.

2. Gebruik in Verloskunde:

Enkele intramuskulêre of intraveneuse inspuiting kan toegedien word om sametrekings te kontroleer of om oordosering met oksitosiese medikamente teë te werk. Die dosis wat gewoonlik

aanbeveel word, is 100 tot 250 µg salbutamol. Dié dosis kan herhaal word na gelang van die pasiënt se reaksie.

NEWE-EFFEKTE EN SPESIALE VOORSORGMATREËLS:

Die onnodige toediening van medikamente gedurende die eerste drie maande van swangerskap is onwenslik.

VENTOLIN INJECTION kan sommige van die perifere arteriole verwyd. Dit kan aanleiding gee tot 'n geringe vermindering van die arteriële druk, en 'n vergoedende vermeerdering van die minuutvolume kan dan plaasvind. 'n Versnelling van die harttempo is meer waarskynlik by pasiënte met 'n normale harttempo, en hierdie vermeerderings is afhanklik van die dosis wat toegedien word. In die geval van pasiënte met reeds gevestigde sinustagikardie, en veral dié in status asthmaticus, sal die harttempo 'n neiging toon om te daal na 'n VENTOLIN INJECTION namate die toestand van die pasiënt verbeter. Die pasiënt kan bewus word van die geringe pyn of branderigheid nadat die inspuiting toegedien is.

VENTOLIN moet met versigtigheid toegedien word aan pasiënte wat ook aan hartkwaal ly.

'n Geringe bewing van die skeletspiere kan by sommige pasiënte opgemerk word.

Gewoonlik is dit die hande wat die duidelikste aangetas word. Hierdie effek staan in verband met die grootte van die dosis wat toegedien word, en word veroorsaak deur 'n regstreekse uitwerking op die skeletspiere. Dit is 'n gemeenskaplike verskynsel van al die beta-adrenergiese stimulanse.

BEKENDE SIMPTOME VAN OORDOSERING EN BESONDERHEDE VAN DIE BEHANDELING DAARVAN:

Die spesifieke teenmiddel vir oordosering met VENTOLIN INJECTION is 'n selektiewe beta-blokkeringsmiddel, toegedien by wyse van intraveneuse inspuiting. Oor die algemeen moet beta-blokkeringsmiddels met versigtigheid voorgeskryf word by pasiënte met 'n geskiedenis van brongspasma, of by pasiënte wat swanger is.

IDENTIFIKASIE:

Die oplossing is kleurloos tot effens strooikleurig en dit het geen reuk nie. Die soortlike gewig en die viskositeit daarvan stem ooreen met dié van water.

AANBIEDING:

1 ml Ampulle in dosies van 5.

BERGINGSANWYSINGS:

Bewaar by of benede 30 °C en beskerm teen lig.

Hou buite bereik van kinders.

REGISTRASIENOMMER:

H/10.2.2/118

NAAM EN BESIGHEIDSADRES VAN DIE APPLIKANT:

GlaxoSmithKline South Africa (Edms) Bpk

Hawkinslaan 39

Epping Industrie 1, 7460

DATUM VAN PUBLIKASIE VAN DIE VOUBILJET:

11 Junie 1981